Literature DB >> 6790999

The metabolism of naltrexone in man.

M E Wall, D R Brine, M Perez-Reyes.   

Abstract

The metabolism and elimination of [15,16-3H2] naltrexone hydrochloride was studied in man following oral and intravenous administration. The same metabolites, although in varying proportions, were observed in both cases; conjugated naltrexone and nonconjugated and conjugated 6 beta-naltrexol were the major metabolites observed in plasma, urine, and feces. 2-Hydroxy-3-O-methyl-6 beta-naltrexol was found in minor quantities. Naltrexone was almost completely in minor quantities. Naltrexone was almost completely absorbed following in the urine and only 5% in the feces. A similar urinary excretion pattern was observed after intravenous administration of naltrexone. In early time periods after oral administration there was a rapid increase in free naltrexone plasma levels up to 1 hr and then gradually declined. A similar pattern was observed for conjugated naltrexone and nonconjugated and conjugated 6 beta-naltrexol. These metabolites were found at levels 4-6 times higher than the parent compound at all times sampled. After intravenous administration, nonconjugated naltrexone plasma levels dropped sharply and continuously. The major metabolites exhibited a pattern closely resembling that found for oral administration. Combined gas chromatography-mass spectrometry was used to validate the presence of naltrexone, 6 beta-naltrexol and 2-hydroxy-3-O-methyl-6 beta-naltrexol in urine. The structure of the latter was rigorously proven by 13C-NMR. No evidence for the presence of noroxymorphone or 3-O-methyl-6 beta-naltrexol could be obtained by gas chromatography-mass spectrometry. The metabolism of naltrexone administered subcutaneously was also determined in two subjects. Larger amounts of 2-hydroxy-3-O-methyl-6 beta-naltrexol were found in plasma than had been present after oral or intravenous administration.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6790999

Source DB:  PubMed          Journal:  NIDA Res Monogr        ISSN: 1046-9516


  6 in total

Review 1.  Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users.

Authors:  D I Quinn; A Wodak; R O Day
Journal:  Clin Pharmacokinet       Date:  1997-11       Impact factor: 6.447

2.  Naltrexone reduces the relative reinforcing value of nicotine in a cigarette smoking choice paradigm.

Authors:  Margaret Rukstalis; Christopher Jepson; Andrew Strasser; Kevin G Lynch; Kenneth Perkins; Freda Patterson; Caryn Lerman
Journal:  Psychopharmacology (Berl)       Date:  2005-01-29       Impact factor: 4.530

Review 3.  Cholestasis and endogenous opioids: liver disease and exogenous opioid pharmacokinetics.

Authors:  Mellar Davis
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 4.  Naltrexone: Not Just for Opioids Anymore.

Authors:  Daniel Sudakin
Journal:  J Med Toxicol       Date:  2016-03

5.  Analysis of naltrexone and its metabolite 6-beta-naltrexol in serum with high-performance liquid chromatography.

Authors:  Pekka Heinälä; Tuuli Lahti; David Sinclair; Kari Ariniemi; Pirjo Lillsunde; Hannu Alho
Journal:  BMC Res Notes       Date:  2012-08-15

6.  The effects of maternally administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data.

Authors:  W O Farid; S A Dunlop; R J Tait; G K Hulse
Journal:  Curr Neuropharmacol       Date:  2008-06       Impact factor: 7.363

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.